|
|
||||||||
1 Department of Pediatrics, Division of Hematology-Oncology and Bone Marrow Transplantation, and Departments of 2 Pulmonary Critical Care Medicine and 3 Physiology, University of Minnesota, Minneapolis, Minnesota 55455; and 4 Amgen, Thousand Oaks, California 91320
We investigated keratinocyte growth factor (KGF) as a pretreatment therapy for idiopathic pneumonia syndrome (IPS) generated as a result of lung damage and allogeneic T cell-dependent inflammatory events occurring in the early peri-bone marrow (BM) transplant (BMT) period. B10.BR (H2k) recipient mice were transplanted with C57BL/6 (H2b) BM with spleen cells after lethal irradiation with and without cyclophosphamide conditioning with and without subcutaneous KGF pretreatment. KGF-pretreated mice had fewer injured alveolar type II (ATII) cells at the time of BMT and exhibited ATII cell hyperplasia at day 3 post-BMT. The composition of infiltrating cells on day 7 post-BMT was not altered by KGF pretreatment, but the frequencies of cells expressing the T-cell costimulatory molecules B7.1 and B7.2 and mRNA for the cytolysin granzyme B (usually increased in IPS) were decreased by KGF. Sera from KGF-treated mice had increases in the Th2 cytokines interleukin (IL)-4, IL-6, and IL-13 4 days after cessation of KGF administration (i.e., at the time of BMT). These data suggest that KGF hinders IPS by two modes: 1) stimulation of alveolar epithelialization and 2) attenuation of immune-mediated injury as a consequence of failure to upregulate cytolytic molecules and B7 ligand expression and the induction of anti-inflammatory Th2 cytokines in situ.
bone marrow transplant; keratinocyte growth factor; type II pneumocytes; cytokines; macrophages; costimulatory molecules
This article has been cited by other articles:
![]() |
A. Panoskaltsis-Mortari, K. V. Tram, A. P. Price, C. H. Wendt, and B. R. Blazar A New Murine Model for Bronchiolitis Obliterans Post Bone Marrow Transplant Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 713 - 723. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Seggewiss, K. Lore, F. J. Guenaga, S. Pittaluga, J. Mattapallil, C. K. Chow, R. A. Koup, K. Camphausen, M. C. Nason, M. Meier-Schellersheim, et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood, July 1, 2007; 110(1): 441 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Blijlevens and S Sonis Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis Ann. Onc., May 1, 2007; 18(5): 817 - 826. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Panoskaltsis-Mortari, J. R. Hermanson, E. Taras, O. D. Wangensteen, I. F. Charo, B. J. Rollins, and B. R. Blazar Post-BMT lung injury occurs independently of the expression of CCL2 or its receptor, CCR2, on host cells Am J Physiol Lung Cell Mol Physiol, February 1, 2004; 286(2): L284 - L292. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Y. Haddad, C. Milla, S. Yang, A. Panoskaltsis-Mortari, S. Hawgood, D. L. Lacey, and B. R. Blazar Surfactant protein A is a required mediator of keratinocyte growth factor after experimental marrow transplantation Am J Physiol Lung Cell Mol Physiol, September 1, 2003; 285(3): L602 - L610. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Panoskaltsis-Mortari, J. R. Hermanson, E. Taras, O. D. Wangensteen, J. S. Serody, and B. R. Blazar Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1alpha (CCL3) after allogeneic BMT in mice Blood, May 1, 2003; 101(9): 3714 - 3721. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dainiak, J. K. Waselenko, J. O. Armitage, T. J. MacVittie, and A. M. Farese The Hematologist and Radiation Casualties Hematology, January 1, 2003; 2003(1): 473 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rossi, B. R. Blazar, C. L. Farrell, D. M. Danilenko, D. L. Lacey, K. I. Weinberg, W. Krenger, and G. A. Hollander Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease Blood, June 28, 2002; 100(2): 682 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Ware and M. A. Matthay Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair Am J Physiol Lung Cell Mol Physiol, May 1, 2002; 282(5): L924 - L940. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. PRINCE, P. H. KARP, T. O. MONINGER, and M. J. WELSH KGF alters gene expression in human airway epithelia: potential regulation of the inflammatory response Physiol Genomics, July 17, 2001; 6(2): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Panoskaltsis-Mortari, P. A. Taylor, J. S. Rubin, A. Uren, L. A. Welniak, W. J. Murphy, C. L. Farrell, D. L. Lacey, and B. R. Blazar Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury Blood, December 15, 2000; 96(13): 4350 - 4356. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. YANG, A. PANOSKALTSIS-MORTARI, D. H. INGBAR, S. MATALON, S. ZHU, E. R. RESNIK, C. L. FARRELL, D. L. LACEY, B. R. BLAZAR, and I. Y. HADDAD Cyclophosphamide Prevents Systemic Keratinocyte Growth Factor-induced Up-Regulation of Surfactant Protein A after Allogeneic Transplant in Mice Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1884 - 1890. [Abstract] [Full Text] |
||||
![]() |
A. Panoskaltsis-Mortari, R. M. Strieter, J. R. Hermanson, K. V. Fegeding, W. J. Murphy, C. L. Farrell, D. L. Lacey, and B. R. Blazar Induction of monocyte- and T-cell-attracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation Blood, August 1, 2000; 96(3): 834 - 839. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |